Medpace was founded in 1992 in Cincinatti, Ohio by Dr. August Troendle, who remains President and CEO. Medpace now has more than 1,500+ personnel working at 30 sites in 45 countries. 40% of its clinical operations employees are in Europe. Medpace describes itself as full service CRO outsourcing and specializes in the planning, management, and execution of clinical trials from early phase studies through Phase IIb-IV and post approval. The company has expertise in metabolic, cardiovascular, oncology, anti-viral/anti-infective, and central nervous system therapeutic areas. In February 2014, European private equity Cinven acquired a majority ownership in Medpace.
Medpace is positioned to support clinical trials across the globe with projects facilitated via regional offices on six continents. Medpace has been noted by Centerwatch as top CRO by investigative sites. Our panel viewed Medpace as.................................
<Thumbnail and link to interactive dashboard to research more...>